Skip to main navigation

Home
News & Presentations
Governance
Financials
Stock Information
Resources

News Releases

News Releases

Year

Jul 13, 2020

Arcutis Initiates Patient Enrollment in the Phase 2b Portion of the Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand Eczema

Jun 22, 2020

Arcutis Enrolls Last Patient in Phase 2 Proof of Concept Clinical Trial Evaluating ARQ-154 (Topical Roflumilast Foam) as a Potential Treatment for Seborrheic Dermatitis

Jun 10, 2020

Arcutis to Present at the Goldman Sachs 41st Annual Global Health Care Conference

Jun 01, 2020

Ayisha Jeter Joins Arcutis as Vice President of Market Access

May 27, 2020

Jay Ramsinghani Joins Arcutis as Vice President of Commercial Strategy and Operations

May 12, 2020

Arcutis Announces First Quarter 2020 Financial Results and Provides Business Update

Apr 27, 2020

Halley E. Gilbert Appointed to Arcutis Board of Directors

Apr 21, 2020

Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema

Mar 23, 2020

Kimberly Lathroum Joins Arcutis as Vice President of Marketing

Mar 16, 2020

Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque Psoriasis

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 20

Print Page

RSS Feeds

Email Alerts

Search

information@arcutis.com

linkedin

Who We Are
Our Focus
Pipeline
Clinical Trials
Investors
Contact
News / Press
Legal Disclaimer

© 2020 Arcutis Biotherapeutics